Rxsight Inc
NASDAQ:RXST
Intrinsic Value
RxSight, Inc. engages in the research, development, manufacture, and sale of light adjustable lenses and related capital equipment. [ Read More ]
The intrinsic value of one RXST stock under the Base Case scenario is 14.29 USD. Compared to the current market price of 52.84 USD, Rxsight Inc is Overvalued by 73%.
Valuation Backtest
Rxsight Inc
Run backtest to discover the historical profit from buying and selling RXST stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Rxsight Inc
Current Assets | 168.4m |
Cash & Short-Term Investments | 127.2m |
Receivables | 20.3m |
Other Current Assets | 20.9m |
Non-Current Assets | 14.1m |
PP&E | 13.3m |
Other Non-Current Assets | 858k |
Current Liabilities | 20.9m |
Accounts Payable | 3.9m |
Accrued Liabilities | 17m |
Other Current Liabilities | 37k |
Non-Current Liabilities | 1.3m |
Long-Term Debt | 118k |
Other Non-Current Liabilities | 1.2m |
Earnings Waterfall
Rxsight Inc
Revenue
|
89.1m
USD
|
Cost of Revenue
|
-35.3m
USD
|
Gross Profit
|
53.8m
USD
|
Operating Expenses
|
-103.9m
USD
|
Operating Income
|
-50.1m
USD
|
Other Expenses
|
1.5m
USD
|
Net Income
|
-48.6m
USD
|
Free Cash Flow Analysis
Rxsight Inc
RXST Profitability Score
Profitability Due Diligence
Rxsight Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
Score
Rxsight Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
RXST Solvency Score
Solvency Due Diligence
Rxsight Inc's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Score
Rxsight Inc's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
RXST Price Targets Summary
Rxsight Inc
According to Wall Street analysts, the average 1-year price target for RXST is 63.97 USD with a low forecast of 61.61 USD and a high forecast of 68.25 USD.
Ownership
RXST Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
RXST Price
Rxsight Inc
Average Annual Return | -8.2% |
Standard Deviation of Annual Returns | 29.69% |
Max Drawdown | -48% |
Market Capitalization | 1.9B USD |
Shares Outstanding | 36 987 600 |
Percentage of Shares Shorted | 4.14% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
RxSight, Inc. engages in the research, development, manufacture, and sale of light adjustable lenses and related capital equipment. The company is headquartered in Aliso Viejo, California and currently employs 87 full-time employees. The company went IPO on 2021-07-30. The firm is engaged in improving the vision of patients following cataract surgery. Its RxSight Light Adjustable Lens system (RxSight system), comprised of its RxSight Light Adjustable Lens (LAL), RxSight Light Delivery Device (LDD) and accessories, is the intraocular lens (IOL) technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. Its LAL is made of photosensitive material that changes shape in response to patterns of ultraviolet (UV) light generated by its LDD. Its RxSight system helps surgeon to performs a standard cataract procedure to implant the LAL, and then uses the LDD to modify the lens with the visual correction needed for the patient’s vision outcomes. Alternative IOL technologies, are not adjustable following the surgery and therefore require patients to make pre-operative choices about their visual preferences.
Contact
IPO
Employees
Officers
The intrinsic value of one RXST stock under the Base Case scenario is 14.29 USD.
Compared to the current market price of 52.84 USD, Rxsight Inc is Overvalued by 73%.